Millennium Management Portfolio holdings
Millennium Management, founded in 1989 by Israel (Izzy) Englander and Ronald Shear and headquartered in New York City, is a global multi-strategy hedge fund managing over $71 billion in assets as of late 2024, employing a decentralized model with over 300 independent trading teams. Operating across equities, fixed income, commodities, currencies, and derivatives, the firm uses a mix of quantitative and fundamental strategies, providing its portfolio managers with capital, infrastructure, and autonomy to pursue diverse investment approaches while enforcing strict risk management. With more than 5,400 employees across offices in London, Hong Kong, Singapore, and beyond, Millennium has evolved from its initial $35 million seed capital—partly from the Belzberg family—into a titan of the hedge fund world, known for its ability to attract top talent and deliver consistent returns. Under Englander’s leadership as chairman and CEO, the firm remains a low-profile yet highly influential force in global finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$200M |
| 2 |
Danaher
DHR
|
+$146M |
| 3 |
iShares 1-5 Year Investment Grade Corporate Bond ETF
IGSB
|
+$138M |
| 4 |
Procter & Gamble
PG
|
+$122M |
| 5 |
RDS.B
Royal Dutch Shell PLC ADS Class B
RDS.B
|
+$109M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.89B |
| 2 |
Microsoft
MSFT
|
+$380M |
| 3 |
Alibaba
BABA
|
+$352M |
| 4 |
Wells Fargo
WFC
|
+$245M |
| 5 |
American Electric Power
AEP
|
+$243M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 11.41% |
| 2 | Technology | 7.27% |
| 3 | Financials | 6.46% |
| 4 | Consumer Discretionary | 5.3% |
| 5 | Industrials | 4.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HIX
3401
Western Asset High Income Fund II
HIX
$350M
| $167K | ﹤0.01% |
33,285
+11,083
| +50% | +$69.9K |
|
|
NBSE
3402
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| $167K | ﹤0.01% |
1,172
-261
| -18% | -$34.5K |
|
|
CRESY
3403
Cresud
CRESY
$796M
| $166K | ﹤0.01% |
49,782
+32,078
| +181% | +$153K |
|
|
FBZ
3404
DELISTED
First Trust Brazil AlphaDEX Fund
FBZ
| $165K | ﹤0.01% |
19,520
-14,989
| -43% | -$220K |
|
3405
X4 Pharmaceuticals
XFOR
$405M
| $165K | ﹤0.01% |
552
-1,659
| -75% | -$471K |
|
3406
YPF
YPF
$20B
| $165K | ﹤0.01% |
39,586
-114,734
| -74% | -$931K |
|
|
RUHN
3407
DELISTED
Ruhnn Holding Limited American Depositary Shares
RUHN
| $165K | ﹤0.01% |
37,623
+16,904
| +82% | +$125K |
|
|
TGI
3408
DELISTED
Triumph Group
TGI
| $164K | ﹤0.01% |
24,334
-43,124
| -64% | -$788K |
|
|
SRNE
3409
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $164K | ﹤0.01% |
+89,093
| New | +$257K |
|
3410
Green Brick Partners
GRBK
$3.09B
| $163K | ﹤0.01% |
20,286
-66,883
| -77% | -$708K |
|
3411
Newmark Group
NMRK
$2.72B
| $163K | ﹤0.01% |
38,320
+22,814
| +147% | +$224K |
|
3412
Sabesp
SBS
$19.1B
| $163K | ﹤0.01% |
114,088
-804,330
| -88% | -$1.97M |
|
3413
Capital Bancorp
CBNK
$613M
| $162K | ﹤0.01% |
12,963
-1,755
| -12% | -$23.5K |
|
|
REV
3414
DELISTED
Revlon, Inc.
REV
| $162K | ﹤0.01% |
14,809
-13,886
| -48% | -$254K |
|
3415
OP Bancorp
OPBK
$237M
| $161K | ﹤0.01% |
21,527
-1,057
| -5% | -$9.61K |
|
|
MGI
3416
DELISTED
MoneyGram International, Inc. New
MGI
| $161K | ﹤0.01% |
122,725
-381,723
| -76% | -$804K |
|
|
INWK
3417
DELISTED
InnerWorkings, Inc.
INWK
| $161K | ﹤0.01% |
+137,957
| New | +$493K |
|
|
CO
3418
DELISTED
Global Cord Blood Corporation
CO
| $161K | ﹤0.01% |
50,590
-40,397
| -44% | -$177K |
|
3419
CALL
Insmed
INSM
$21.3B
| $160K | ﹤0.01% |
10,000
-90,000
| -90% | -$2.13M |
|
3420
CALL
MacroGenics
MGNX
$243M
| $160K | ﹤0.01% |
27,500
-272,500
| -91% | -$2.47M |
|
3421
Natural Health Trends
NHTC
$15.8M
| $160K | ﹤0.01% |
48,582
-12,555
| -21% | -$50.9K |
|
|
UCTT
3422
Ultra Clean Holdings
UCTT
$3.79B
| $160K | ﹤0.01% |
11,619
-67,532
| -85% | -$1.43M |
|
|
CALA
3423
DELISTED
Calithera Biosciences, Inc
CALA
| $157K | ﹤0.01% |
1,771
-15,339
| -90% | -$1.83M |
|
3424
Genasys
GNSS
$78.3M
| $155K | ﹤0.01% |
47,280
+24,513
| +108% | +$78.3K |
|
3425
CoreCivic
CXW
$3B
| $154K | ﹤0.01% |
+13,809
| New | +$207K |
|
Similar funds
Millennium Management's Q1 2020 Portfolio in Review
As of Q1 2020, Millennium Management held 4,928 positions worth $44.5B, down 44% from $79.9B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Millennium Management withdrew a net $21.4B in Q1 2020, closing 1,154 positions and reducing 1,745 holdings. Its most notable exit was Becton Dickinson, an estimated $152M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 11% of assets, up from 9.7% a quarter earlier, followed by Technology and Financials.
Against the trend, Millennium Management opened a new position in Danaher worth $133M.
- Millennium Management's largest Q1 2020 buy was Danaher: 1,082,448 shares worth $133M.
- Millennium Management added most to Allergan plc in Q1 2020, an estimated $200M increase.
- Millennium Management's biggest Q1 2020 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $3.89B.
- Millennium Management fully exited Becton Dickinson in Q1 2020, selling an estimated $152M.
- Millennium Management's ten largest holdings make up 18% of its $44.5B portfolio in Q1 2020.
- Millennium Management opened 789 new positions and closed 1,154 in Q1 2020.
- Millennium Management's portfolio value fell 44% quarter-over-quarter to $44.5B.
Based on Millennium Management's 13F filing for Q1 2020, filed 14 May 2020.